The most important breakthroughs despite the ongoing Covid‐19 pandemic include the incorporation of MET (Mesenchymal Epithelial Transition factor), RET (Rearranged during transfection), and KRAS (Kirsten Rous sarcoma virus) in biomarker testing for NSCLC as well as the recent recommendation of performing broad panel‐based testing in patients of squamous histology as well.1, 2. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.